Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Glycoprotein – e.g. – mucins – proteoglycans – etc.
Reexamination Certificate
2006-08-29
2006-08-29
O'Hara, Eileen B. (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Glycoprotein, e.g., mucins, proteoglycans, etc.
C536S023400, C435S069100, C530S399000
Reexamination Certificate
active
07098318
ABSTRACT:
The present invention relates to a fusion protein having enhanced in vivo activity of erythropoietin wherein a carboxy terminal peptide fragment of thrombopoietin is fused with the carboxy terminal of human erythropoietin. This fusion protein has highly enhanced in vivo half-life due to increased carbohydrate content without loss of the inherent activity of erythropoietin, and does not cause any antigenicity when applied to the human body.
REFERENCES:
patent: 6342220 (2002-01-01), Adams et al.
patent: 6608183 (2003-08-01), Cox, III
Wang et al., Virology 15: 5-8, 2001.
Chung Bo-Sup
Kim Ki-Wan
Lee Dong-Eok
Oh Myung-Suk
Park Ji-Sook
Chandra Gyan
Cheil Jedang Corporation
Corless Peter F.
Edwards Angell Palmer & & Dodge LLP
O'Day Christine C.
LandOfFree
Fusion protein having enhanced in vivo activity of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fusion protein having enhanced in vivo activity of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion protein having enhanced in vivo activity of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3701366